NovaBridge FY25 net loss widens to $88.3 million; revenue posts no revenue

NovaBridge Biosciences

NovaBridge Biosciences

NBP

0.00
  • NovaBridge posted a net loss of USD 88.3 million for fiscal year 2025, widening from USD 22.2 million a year earlier.
  • Revenue was unchanged at no revenue, versus USD 632,000 in 2023.
  • Operating loss widened to USD 94.3 million as research and development expenses more than doubled to USD 62.9 million.
  • Cash and cash equivalents totaled USD 210.6 million at year-end, with net cash used in operating activities of USD 20.6 million.
  • NovaBridge forecast cash, cash equivalents and short-term investments of USD 210.8 million will fund operations into Q4 2028, while highlighting givastomig Phase 2 first-patient enrollment and plans to start a registrational Phase 3 trial as early as Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001778016-26-000002), on April 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.